Clive Dix talks Proactive London's Andrew Scott through its interim results to January 2020.
Dix says its NRF-2 activator programme for sickle cell disease and pulmonary arterial hypertension is progressing and it is down to a short-list of three molecules.
29 April 2020 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces its interim results for the six months ended 31 January 2020.
31 January 2020 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, announces that at its Annual General Meeting, held today at 11:00 am at Panmure Gordon & Co., One New Change, London EC4M 9AF, all resolutions were duly passed.
17 January 2020 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that the Annual General Meeting of the Company will be held on 31 January 2020, at 11:00am, at Panmure Gordon, One New Change, London. The Annual Report and Financial Statements for the year ended 31 July 2019, has been published and sent to shareholders.
Dr Clive Dix, Chief Executive Officer, and members of the management team host this live presentation for analysts - watch this on-demand replay.
9 December 2019 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, is pleased to note the announcement that Altasciences has been selected by Indivior PLC to conduct "A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of INDV-2000 (C4X3256) Under Fasting and Fed Conditions in Healthy Volunteers”.
13 November 19 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that at the General Meeting held earlier today in connection with the Company’s Placing, Subscription and Open Offer, details of which were announced on 24 October 2019, all resolutions put to shareholders were duly passed.